Dyadic International Inc. a global biotechnology company, has entered into a collaboration with Syngene International Limited, an integrated research, development, and manufacturing services company, to develop a COVID-19 vaccine candidate that can protect against the emerging variants of concern and which can be manufactured affordably, at very large scale, using Dyadic’s proprietary C1-cell protein production platform.   Mahesh Bhalgat, COO, Syngene International stated, “We look f...